Skip to main content

Research Repository

Advanced Search

All Outputs (7)

Correction to: Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (npj Primary Care Respiratory Medicine, (2024), 34, 1, (6), 10.1038/s41533-024-00363-0) (2024)
Journal Article
Crooks, M. G., Cummings, H., Morice, A. H., Sykes, D., Brooks, S., Jackson, A., & Xu, Y. (2024). Correction to: Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (npj Primary Care Respiratory Medicine, (2024), 34, 1, (6), 10.1038/s41533-024-00363-0). NPJ Primary Care Respiratory Medicine, 34(1), Article 19. https://doi.org/10.1038/s41533-024-00376-9

Correction to: npj Primary Care Respiratory Medicine34, 6 (2024) https://doi.org/10.1038/s41533-024-00363-0, published online 29 April 2024 In this article the Table 2 columns were incorrectly structured. The original article has been corrected.

Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial (2024)
Journal Article
Devereux, G., Cotton, S., Nath, M., McMeekin, N., Campbell, K., Chaudhuri, R., …Lipworth, B. J. (2024). Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial. Journal of the American Medical Association, https://doi.org/10.1001/jama.2024.8771

Importance: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Observational studies report that β-blocker use may be associated with reduced risk of COPD exacerbations. However, a recent trial repor... Read More about Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of Exacerbation: The BICS Randomized Clinical Trial.

Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites (2024)
Journal Article
Crooks, M. G., Cummings, H., Morice, A. H., Sykes, D., Brooks, S., Jackson, A., & Xu, Y. (2024). Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites. NPJ Primary Care Respiratory Medicine, 34(1), Article 6. https://doi.org/10.1038/s41533-024-00363-0

Short-acting beta-agonist (SABA) over-use in asthma is harmful for patients and the environment. The Investment and Impact Fund (IIF) 2022/2023 financially rewarded English primary care networks that achieved specific targets, including reducing SABA... Read More about Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites.

The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies (2024)
Journal Article
Sykes, D. L., Mason, P., Rahunathan, N., Hart, S. P., Morice, A. H., & Crooks, M. G. (2024). The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies. Lung, https://doi.org/10.1007/s00408-024-00729-8

Introduction: Azithromycin is an effective treatment for various respiratory conditions but its effect on cough is poorly understood. We synthesised data from randomised controlled trials (RCTs) and noncomparative studies (NCT) examining its effect o... Read More about The Effect of Long-Term Azithromycin on Objective and Subjective Cough in Chronic Respiratory Disease: A Systematic Review and Meta-analysis of Randomised Controlled Trials and Noncomparative Studies.

Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men (2024)
Journal Article
Friedrich, C., Singh, D., Francke, K., Klein, S., Hetzel, T., Zolk, O., Gashaw, I., Scheerans, C., & Morice, A. (2024). Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men. British Journal of Clinical Pharmacology, https://doi.org/10.1111/bcp.16091

Aims: We report on investigations exploring the P2X3-receptor antagonist filapixant's effect on taste perception and cough-reflex sensitivity and describe its pharmacokinetics, including its CYP3A4-interaction potential. Methods: In a randomized, pla... Read More about Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men.